

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-20 (canceled).

Claim 21 (new): A method for treating or preventing cancer in a HLA-A26 positive patient, which comprises administering an effective amount of a peptide as set forth in any one of SEQ ID NOs: 2, 8 and 9 to a HLA-A26 positive patient.

Claim 22 (new): The method according to Claim 21, wherein the patient is positive for WT1.

Claim 23 (new): The method according to Claim 21, wherein the peptide is SEQ ID NO: 2.

Claim 24 (new): The method according to Claim 21, wherein the peptide is SEQ ID NO: 8.

Claim 25 (new): The method according to Claim 21, wherein the peptide is SEQ ID NO: 9.

Claim 26 (new): A method for inducing CTL that specifically recognize a complex of an HLA-A26 antigen and a peptide as set forth in any one of SEQ ID NOs: 2, 8 and 9,

which comprises contacting peripheral blood mononuclear cells derived from an HLA-A26 positive subject with the peptide.

Claim 27 (new): The method according to Claim 26, wherein the subject is positive for WT1.

Claim 28 (new): The method according to Claim 26, wherein the peptide is SEQ ID NO: 2.

Claim 29 (new): The method according to Claim 26, wherein the peptide is SEQ ID NO: 8.

Claim 30 (new): The method according to Claim 26, wherein the peptide is SEQ ID NO: 9.